Please assess the completion status of the following clinical trial:

Trial Title: Antipsychotic Therapy and First Episode

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients, from 18 to 65 years of age at Visit 1~* Patients must achieve a level of understanding and expressive capacity sufficient to communicate adequately with the study coordinator and to participate in cognitive testing.~* Patients must agree to cooperate with all tests and examinations required by the protocol. They must be willing to comply fully with treatment~* Patient must understand the nature of the study and must sign an informed consent document.~* Patients must be Cantonese speaking Han Chinese~* Patients must be diagnosed, according to the SCID for DSM-IV, with schizophrenia, schizoaffective disorder or schizophreniform psychosis.~* Patients must have good response to anti-psychotic treatment by achieving a rating of 2 or below in Clinical Global Impression Scale (CGI) Severity of illness; a rating of 4 or below in Improvement scale, and a rating of 3 or below in (conceptual disorganization, unusual thought content), a rating of 2 or below in (delusion, hallucinatory behavior) and a rating of 4 or below in (Suspiciousness) of Positive and Negative Syndrome Scale (PANSS) for at least 8 weeks~Exclusion Criteria:~* Female patients who are either pregnant or lactating.~* Patients previously on clozapine should be excluded from the study~* Significant medical illnesses including seizures.~* DSM-IV substance (alcohol or other drugs) abuse or dependence within the past 3 months.~* Judged clinically to be at serious suicidal risk.~* Treatment with an injectable depot neuroleptic within less than one of the patient's dosing intervals between depot neuroleptic injections prior to study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).